Breaking News, Collaborations & Alliances

Amgen, AstraZeneca Enter Inflammation Alliance

Will jointly develop and commercialize five Amgen monoclonal antibodies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen and AstraZeneca entered an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827). AZ will make a one-time $50 million upfront payment and the companies will share costs and profits. AZ will lead the development and commercial strategy for AMG 139, AMG 157 and AMG 181, while Amgen will lead brodalumab and AMG 557 development. Amgen will promote dermatology indicatio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters